Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03450343 · ClinicalTrials.gov registry record · Phase 1
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03450343: Completed Phase 1 study, sponsored by Medical University of South Carolina.
NCT03450343 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03450343, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.
Primary Outcome
A 3+3 dose-escalation design will be used to determine the recommended phase II dose.
Interventions
- DRUG Oral azacitidine
- DRUG R-ICE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 1 |
What the finished NCT03450343 record still lists
NCT03450343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Oral azacitidine is the first listed.
NCT03450343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03450343 about?
NCT03450343 is a clinical study titled "Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma". The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.
What is the current status of trial NCT03450343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-04-04. Estimated completion is 2024-01-30.
What interventions are being tested in trial NCT03450343?
The interventions under investigation include: Oral azacitidine (DRUG), R-ICE (DRUG).
Who is sponsoring clinical trial NCT03450343?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03450343's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI